금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
Owner of car searched by police after Beijing tower plane crash identified
Vehicle was at airfield from where aircraft that hit Citic Tower took off...
Trump’s power is waning. But is Trumpism here to stay?
As a war-damaged president faces midterms, a battle looms for the future of US conservatism that the...
Apple seeks to buy memory chips from blacklisted Chinese company
The iPhone maker wants Trump administration to sign off on purchases to ease pressure from rising ch...
Mortgage rates tick down, purchase demand softens
Nine energy service expects Q2 revenue of $136M-$146M and adjusted EBITDA of $10M-$15M following Chapter 11 exit
CTS Corporation declares $0.04 dividend
RBC Global Asset Management announces monthly distributions
RBC Global Asset Management announces monthly distributions
CVRx rebounds as Humana issues Medicare policy for Barostim
SELF Stock Declines Post Q1 Earnings Despite Occupancy Gains
Global Self Storage's first-quarter 2026 revenues increase on higher occupancy and rent hikes, but rising expenses squeeze profits and cash flow.
Mortgage rates tick lower to 6.36%. Here’s why the decrease probably won’t last.
A year ago, mortgage rates averaged 6.81%.
Euro slides as resilient US sales fuel Dollar rally
EUR/USD edges lower for the third consecutive day during the North American session, down 0.22%, as US economic data showed consumers' resilience. In contrast, jobless benefits data showed a slight in ...
Dow Jones Industrial Average futures rebound above 50,000
Dow Jones Industrial Average (DJIA) futures traded above 50,000 in the overnight and premarket sessions on Thursday, more than reversing the modest pullback in the cash index on Wednesday.
Swiss Franc dips as strong US data, hawkish Fed commentary support Dollar
USD/CHF advances toward 0.7830 on Thursday, gaining 0.15% on the day at the time of writing, supported by renewed demand for the US Dollar (USD) following a series of solid economic releases in the Un ...
Biogen Moves Alzheimer’s Drug to Late-Stage Trials. Wall Street Thinks It’s a Mistake.
Biogen’s diranersen showed ‘robust reductions’ in key biomarkers during a Phase 2 trial, the biotech said.